AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19221871
Drug: Clinic-based treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-based treatment (CLINIC)
Trial: 17451369
Drug: Teriparatide treatment
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide treatment
Trial: 7698050
Drug: Topical human
RxNorm normalized name: thrombin topical human topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical human recombinant basic fibroblast growth factor (bFGF) applied daily for 6 weeks, then twice a week for 12 weeks
Trial: 7698050
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied daily for 6 weeks, then twice a week for 12 weeks
Trial: 27530106
Drug: Directives on
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directives on opioid prescribing released by the Veterans Health Administration (VHA) or the Food and Drug Administration (FDA)
Trial: 25992918
Drug: Low-dose prednisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisone (15 mg/d)
Trial: 25992918
Drug: Medium-dose prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium-dose prednisone (30 mg/d)
Trial: 25992918
Drug: High-dose prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisone (60 mg/d)
Trial: 19565728
Drug: Compound PuHuang
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound PuHuang Granules
Trial: 19565728
Drug: NaoXueShuan Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaoXueShuan Tablets
Trial: 1437435
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (0.15 mg/kg per dose) and ipratropium bromide (250 micrograms per dose)
Trial: 1437435
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol and normal saline (placebo)
Trial: 26646751
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of hydrocortisone (0.4‐0.6 mg/kg body weight/day)
Trial: 18355797
Drug: Negative-pressure wound
RxNorm normalized name: Microcyn Negative-Pressure Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure wound therapy (NPWT) using the Vacuum-Assisted Closure (V.A.C.) system
Trial: 18355797
Drug: Standard moist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard moist wound therapy (MWT)
Trial: 16043008
Drug: Participants taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants taking prescribed medications
Trial: 12390105
Drug: Dextromethorphan 10
RxNorm normalized name: DEXTROMETHORPHAN 10MG CHEWABLE TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 10 mg
Trial: 7800005
Drug: Antibacterial treatment
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial treatment (120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, each given orally four times a day for one week)
Trial: 7800005
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg orally per day for four weeks)
Trial: 30948276
Drug: RB-CHOP (Rituximab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RB-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone + Bortezomib 1.3 mg/m2 intravenously or 1.6 mg/m2 subcutaneously on days 1 and 8 for cycles two to six)
Trial: 25127655
Drug: Reduced-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose warfarin for 3-6 days aiming for INR < 1.7
Trial: 25127655
Drug: Interrupted warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted warfarin for 5 days with LMWH bridging for 2.5 days
Trial: 22622649
Drug: Levosimendan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.1 μg/kg/min for 24 hours)
Trial: 22622649
Drug: Milrinone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (0.5 μg/kg/min for 24 hours)
Trial: 19922961
Drug: RSG (rosiglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG (rosiglitazone 8 mg/d)
Trial: 19922961
Drug: RSG +
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RSG + EX (rosiglitazone 8 mg/d plus exercise training)
Trial: 17672962
Drug: Yunnan Baiyao
RxNorm normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yunnan Baiyao (500 mg four times daily for 3 days before surgery)
Trial: 15615872
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (140 mg/day; n=26)
Trial: 9698950
Drug: hyperbaric lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hyperbaric lidocaine 50 mg/ml diluted with CSF 1:1 (Group L)
Trial: 9698950
Drug: hyperbaric mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric mepivacaine 40 mg/ml (Group M)
Trial: 9698950
Drug: hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric bupivacaine 5 mg/ml (Group B)
Trial: 8681269
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy using a fluorescent light box (2500 lux for 2 hours per day)
Trial: 8681269
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy using a fluorescent light box (10,000 lux for 30 minutes)
Trial: 158570
Drug: tretinoin lotion
RxNorm normalized name: tretinoin Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tretinoin lotion 0.05% applied in the morning and benzoyl peroxide 5% and 10% applied at night
Trial: 28463827
Drug: Taurolidine lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolidine lock solution
Trial: 28463827
Drug: Standard saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard saline solution (Control)
Trial: 9990415
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% cream
Trial: 19958063
Drug: Educational outreach
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational outreach visits for reducing selected antibiotics (14 practices)
Trial: 19958063
Drug: Educational outreach
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational outreach visits for improving antidepressant prescribing (14 practices)
Trial: 17944686
Drug: lopinavir/saquinavir/ritonavir (LPV/SQV/r;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/saquinavir/ritonavir (LPV/SQV/r; 400/1000/100 mg bid)
Trial: 17944686
Drug: indinavir/ritonavir (IDV/r;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indinavir/ritonavir (IDV/r; 800/100 mg bid) plus two NRTIs
Trial: 15356029
Drug: Metformin (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (425 mg/d) for 6 months in prepubertal girls
Trial: 15356029
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg/d) for 12 months in postpubertal girls
Trial: 8331334
Drug: Placebo Treatment
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Treatment
Trial: 8323306
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (bacitracin plus Band‐Aid)
Trial: 28700805
Drug: Lisdexamfetamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisdexamfetamine (50 or 70 mg)
Trial: 16473558
Drug: Extended-release divalproex
RxNorm normalized name: divalproex sodium Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release divalproex sodium (divalproex-ER) every 12 hours (q12h)
Trial: 16473558
Drug: Once-daily divalproex-ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily divalproex-ER
Trial: 10885442
Drug: Hypericum oil
RxNorm normalized name: Hypericum oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum oil (hypericin 110 microg/mL)
Trial: 10885442
Drug: Hypericum ointment
RxNorm normalized name: Hypericum oil
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum ointment (hypericin 30 microg/mL)
Trial: 1468386
Drug: Morphine (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (group M) - 50 micrograms/kg per h, increased to 100 micrograms/kg per h if needed
Trial: 1468386
Drug: Morphine with
RxNorm normalized name: opium alkaloids with morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine with Pancuronium (group M+P)
Trial: 6331136
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg purified brain gangliosides for six months
Trial: 30976851
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg/day, n=12, MET group)
Trial: 30976851
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg/day, n=12, CONT group)
Trial: 25033565
Drug: Tianeptine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (administered for three days)
Trial: 25033565
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline (administered for three days)
Trial: 25033565
Drug: Imipramine (sub-chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (sub-chronic administration for 6 days)
Trial: 20417447
Drug: atorvastatin 80mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 80mg
Trial: 16152757
Drug: IFN-alpha 3
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha 3 MIU subcutaneously three times a week plus 100 mg MMPD (every 8 h) for 4 weeks
Trial: 16152757
Drug: IFN-alpha 3
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha 3 MIU subcutaneously three times a week plus 300 mg MMPD (every 8 h) for 4 weeks
Trial: 11966932
Drug: Amoxycillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (250 mg) and Metronidazole (200 mg) (AM)
Trial: 11966932
Drug: Lactate capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate capsules and Metronidazole (PM)
Trial: 11966932
Drug: Amoxycillin and
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin and Calcium Lactate tablets (AP)
Trial: 10424912
Drug: Vigorous oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigorous oral hydration (20 mL/kg)
Trial: 1602947
Drug: High potency
RxNorm normalized name: High Potency B+C
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High potency multivitamin-mineral supplement
Trial: 26670986
Drug: Daily changing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily changing load (DCL)
Trial: 21697819
Drug: Functional yogurt
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional yogurt NY-YP901 (150 ml, twice a day for 8 weeks)
Trial: 21697819
Drug: Placebo yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo yogurt (twice a day for 8 weeks)
Trial: 16889444
Drug: Olanzapine/fluoxetine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/fluoxetine combination (OFC) 6/25, 6/50, 12/25, or 12/50 mg/day
Trial: 16889444
Drug: Lamotrigine titrated
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine titrated to 200 mg/day
Trial: 14748761
Drug: Control (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (other chemotherapeutic agents)
Trial: 11251135
Drug: Preemptive multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive multimodal analgesia (IV ketorolac 30 mg, intra-articular ropivacaine 0.25% + morphine 2 mg + epinephrine 1:200,000, femoral nerve block with ropivacaine 0.25%) administered 15 minutes before skin incision
Trial: 11251135
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (multimodal analgesia administered immediately after skin closure)
Trial: 1606393
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (1.2 U/kg/week)
Trial: 29454501
Drug: Nutricia preOp®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutricia preOp® (800 ml on the night before surgery/400 ml 2-3 h preoperatively)
Trial: 29454501
Drug: Placebo (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (800 ml on the night before surgery/400 ml 2-3 h preoperatively)
Trial: 22657252
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate oral powder (1000 mg, 3000 mg/d for 10 doses)
Trial: 22657252
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate chewable tablet (1000 mg, 3000 mg/d for 10 doses)
Trial: 22657252
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (oral powder and chewable tablet)
Trial: 18849849
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (AP)
Trial: 18849849
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (NP)
Trial: 11817468
Drug: 15% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% carbamide peroxide bleaching agent with reservoirs
Trial: 11817468
Drug: 15% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% carbamide peroxide bleaching agent without reservoirs
Trial: 10072242
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0)
Trial: 8590744
Drug: Thrombolytic or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic or angioplasty therapy
Trial: 2405738
Drug: Preanesthetic medication
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preanesthetic medication
Trial: 2405738
Drug: No preanesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preanesthetic medication
Trial: 511251
Drug: Formolized KFD
RxNorm normalized name: Formol
DrugBank: Formaldehyde (DB03843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formolized KFD virus vaccine (two doses administered to 1405 individuals)
Trial: 511251
Drug: Formolized KFD
RxNorm normalized name: Formol
DrugBank: Formaldehyde (DB03843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formolized KFD virus vaccine
Trial: 28107853
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intervention, usual daily activities)
Trial: 26051567
Drug: Inhalation aromatherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation aromatherapy with 2% lavender essential oil for 20 min
Trial: 24016218
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 fortified food (1.4 μg/day)
Trial: 21235333
Drug: Systemic antimicrobials
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antimicrobials (500 mg amoxicillin + 250 mg metronidazole; three times a day for 10 days)
Trial: 19660681
Drug: CNS prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS prophylaxis during initial treatment for aggressive NHL
Trial: 31988972
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg once daily
Trial: 8790569
Drug: Interferon-alpha 2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2a (2.5 MIU m-2, 5.0 MIU m-2, 10.0 MIU m-2) three times weekly by intramuscular injection for 12-24 weeks
Trial: 30503831
Drug: Short-term intensive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intensive insulin therapy (IIT) consisting of basal detemir and premeal insulin aspart
Trial: 25395350
Drug: 75 g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g oral glucose
Trial: 25395350
Drug: 100 g standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g standard noodle
Trial: 23664707
Drug: HAA (homoharringtonine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAA (homoharringtonine 2 mg/m² per day on days 1-7, cytarabine 100 mg/m² per day on days 1-7, and aclarubicin 20 mg/day on days 1-7)
Trial: 23664707
Drug: HAD (homoharringtonine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAD (homoharringtonine 2 mg/m² per day on days 1-7, cytarabine 100 mg/m² per day on days 1-7, and daunorubicin 40 mg/m² per day on days 1-3)
Trial: 23664707
Drug: DA (daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA (daunorubicin 40-45 mg/m² per day on days 1-3 and cytarabine 100 mg/m² per day on days 1-7)
Trial: 10498385
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Aspirin
Trial: 10498385
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Pycnogenol
Trial: 10498385
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg Pycnogenol
Trial: 10498385
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Pycnogenol
Trial: 8698504
Drug: Hexavalent PorA
RxNorm normalized name: PORACTANT ALFA
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hexavalent PorA outer membrane vesicle vaccine (50 or 100 micrograms)
Trial: 8698504
Drug: Hexavalent PorA
RxNorm normalized name: PORACTANT ALFA
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hexavalent PorA outer membrane vesicle vaccine
Trial: 2069220
Drug: Bacteriostatic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteriostatic saline flush solution
Trial: 2069220
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline flush solution
Trial: 6897123
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg atropine intravenously
Trial: 6897123
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg pirenzepine intravenously
Trial: 6897123
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pirenzepine perorally twice daily for 4 days
Trial: 6897123
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg L-hyoscyamine perorally twice daily for 4 days
Trial: 22631626
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
Trial: 22631626
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (1.0 mg/kg) (MS)
Trial: 22631626
Drug: No sedative
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sedative (PS)
Trial: 11692987
Drug: Metamizol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizol (1 g intramuscular every 8 hours)
Trial: 11692987
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg intramuscular every 12 hours)
Trial: 8434332
Drug: placebo-control treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo-control treatment
Trial: 3303918
Drug: alpha 2-interferon
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alpha 2-interferon as an intranasal spray
Trial: 29630112
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (external radiation, systemic chemotherapy or conservative treatment)
Trial: 17595451
Drug: Euthyrox (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euthyrox (50 mkg daily) after PEI
Trial: 3064774
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic treatment (0)
Trial: 27905916
Drug: 100 to
RxNorm normalized name: Zionodil 100 Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 to 250 mg lisdexamfetamine, dispensed daily on site, over an 8-week period